The Journal of Biopharmaceutical Statistics , a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:

    Drug, device, and biological research and development
    Drug screening and drug design
    Assessment of pharmacological activity
    Pharmaceutical formulation and scale-up
    Preclinical safety assessment
    Bioavailability, bioequivalence, and pharmacokinetics
    Phase, I, II, and III clinical development including complex innovative designs 
    Premarket approval assessment of clinical safety
    Postmarketing surveillance
    Big data and artificial intelligence and applications   

Peer Review Policy

All submitted manuscripts are subject to initial appraisal by the Editors. If found suitable for further consideration, papers are subject to peer review by two independent, anonymous expert referees, each delivering at least one report under the guidance of a team of expert Associate Editors. All peer-review is single anonymous and submissions can be made online via the Submission Portal. 

Publishing Ethics Statement

The Journal adheres to the highest standards of publishing ethics, with rigorous processes in place to ensure this is achieved. Taylor & Francis is a member of the Committee of Publication Ethics (COPE) and utilizes Similarity Check for all Journals.

More information on our ethical standards and policies can be found here:

http://authorservices.taylorandfrancis.com/ethics-for-authors/.

The Journal has an appeals and complaints policy which can be viewed here:

https://authorservices.taylorandfrancis.com/peer-review-appeals-and-complaints-from-authors/
Author Benefits

Editorial Board
Author Services

My Authored Works

Publication office: Taylor & Francis, Inc., 530 Walnut Street, Suite 850, Philadelphia, PA 19106.

Editor-in-Chief:
Shein-Chung Chow 
Professor, Biostatistics and Bioinformantics 
Duke University School of Medicine 
2424 Erwin Road 
Durham, NC 27705 
Email: sheinchung.chow@duke.edu 
Managing Editor:
Victoria Chang 
BeiGene, Ltd. 
2955 Campus Drive 
San Mateo, CA 94403 
Tel: 669-246-8342 
Email: changvick@gmail.com 
Honorary Advisory/Editorial Board Members: 
S. Altan - Johnson & Johnson, Raritan, NJ
A. Lawrence Gould (Editor 2000-2002) - Merck & Co., Inc., Blue Bell, PA
G. Campbell - FDA/CDRH, Rockville, MD
V. Chinchilli - Pennsylvania State University, Hershey, PA
L. Edler - German Cancer Research Center, Heidelberg, Germany
D. Follmann - NIAID, National Institutes of Health, Bethesda, MD
P. P. Gallo - Novartis Pharmaceuticals, East Hanover, NJ
F. Kianifard - Novartis Pharmaceuticals, East Hanover, NJ
G. Koch - University of North Carolina, Chapel Hill, NC
J.-P. Liu - National Taiwan University, Taipei, Taiwan 
D. F. Moore - Rutgers University, New Brunswick, NJ
A. Pong - Merck Research Institute, Morris, NJ
S. M. Snapinn - Amgen, Inc., Thousand Oaks, CA
R. Tamura - Eli Lilly and Company, Indianapolis, IN
Y. Tsong - FDA/CDER, Rockville, MD
D. Wright - MHPRA, London, United Kingdom
D. Zelterman - Yale Cancer Center, New Haven, CT
 
Book Review Editor 

A. Pong - Merck Research Institute, Morris, NJ

Associate Editors:

G. Aras - Amgen Inc., Thousand Oaks, CA 
B. Binkowitz - Shionogi Inc., Florham Park, NJ 
C.-F. Burman - AstraZeneca, Molndal, Sweden
I. S. F. Chan - AbbVie, North Chicago, IL 
M. Chang - Boston University, Boston, MA 
B. Cheng - Columbia University, New York, NY 
V. Chinchilli - Pennsylvania State University, Hershey, PA 
Y.-L. Chiu - AbbVie, North Chicago, IL 
V. Dragalin - Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA 
G. Dong - iStats Inc., Long Island City, NY 
X. Dong - Amgen, Washington DC 
V. Dragalin - Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA 
H. Fu - Eli Lilly and Company, Indianapolis, IN 
M. Gamalo-Sieber s - Eli Lilly and Company, Indianapolis, IN
T. Hamasaki - National Cerebral and Cardiovascular Center, Osaka, Japan 
C.-F. Hsiao - National Health Research Institutes, Zhunan, Taiwan 
J. C. Hsu - Ohio State University, Columbus, OH 
H. M. J. Hung - CDER/FDA, Silver Springs, MD 
S. H. Jung - Duke University, Durham, NC 
S.-H. Kang - Yonsei University, Seoul, Korea 
M. Kieser - University of Heidelberg, Heidelberg, Germany 
G. Koch - University of North Carolina, Chapel Hill, NC 
G. F. Liu - Merck & Co., Inc., North Wales, PA
T. Lu - SUNY Albany, Rensselaer, NY 
O. Marchenko - Bayer, Whippany, NJ 
A.J. Sankoh - Vertex Pharmaceuticals, Cambridge, MA
M. Shen - FDA, Silver Spring, MD 
J-M Shoung - Johnson & Johnson, Raritan, NJ 
S.-B. Tan - National Medical Research Council, Singapore
S.-K. Tse - City University of Hong Kong, Kowloon, Hong Kong 
Y. Tsong - FDA/CDER, Rockville, MD
H.-H. Tsou - National Health Research Institutes, Taiwan 
J.-Y. Tzeng - North Carolina State University, Raleigh, NC 
S. Wang - Boehringer Ingelheim Pharmaceuticals, Inc. 
H. Xu - Johnson & Johnson, Titusville, NJ 
L. Yue - FDA/CDRH, Rockville, MD 
J. Zhang - University of Maryland, College Park, MD 
L. Zhang - AbbVie, North Chicago, IL 

Past Editors:
Karl E. Peace (Founding Editor, 1990-1999) - Georgia Southern University, Statesboro, GA